key: cord-0757100-f1iklvp2
authors: Zheng, Kenneth I.; Gao, Feng; Wang, Xiao-Bo; Sun, Qing-Feng; Pan, Ke-Hua; Wang, Ting-Yao; Ma, Hong-Lei; Liu, Wen-Yue; George, Jacob; Zheng, Ming-Hua
title: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
date: 2020-04-19
journal: Metabolism
DOI: 10.1016/j.metabol.2020.154244
sha: edd1b35fa72b435d3cb9cf363d9c9e841d8bc3b7
doc_id: 757100
cord_uid: f1iklvp2

Abstract Background & Aims. Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. Methods 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25 kg/m2. Results The presence of obesity in MAFLD patients was associated with a ~ 6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19–27.91, p = .029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16–34.54, p = .033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. Conclusions Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.

Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. [1] Preliminary data suggests that obesity may aggravate the severity of respiratory diseases and of COVID-19. [2] Patients with metabolic associated fatty liver disease (MAFLD), [3] formerly known as non-alcoholic fatty liver disease, are often obese and have additional metabolic risk factors which may translate to a greater risk from respiratory diseases. [4] [5] [6] [7] It is currently not known whether MALFD patients are also more likely to have greater COVID-19 severity of illness. This study investigated the association between MAFLD and COVID-19 severity.

We consecutively enrolled 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, and Ruian People's Hospital) between January 1, 2020 and February 29, 2020. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. [3] Sixty six COVID-19 patients with MAFLD were included in the analyses and were divided into two groups [those with obesity (n=45) and those without (n=21)]. All patients received standard treatment based on the COVID-19 Management Guidance (7th edition). [8] This study was approved by the local ethics review boards of all three hospitals. The requirement for written informed consent was waived for use of the We collected demographic information and past medical history from all patients.

Laboratory parameters were tested on the first day of hospital admission. Body weight and height were measured by trained examiners on admission. Body mass index (BMI) was calculated using the formula weight (kilograms) divided by height (meters) squared. Obesity was defined as BMI greater than 25 kg/m 2 . [9] Diabetes, hypertension and dyslipidemia were diagnosed based on established criteria. [10] All patients denied a history of chronic obstructive or restrictive pulmonary disease.

Continuous variables are expressed as mean ± SD and compared using either the Student's t-test for normally distributed variables or the Mann-Whitney test for non-normally distributed variables. Continuous variables were tested for normality using the Shapiro-Wilk test. Differences between categorical variables was examined J o u r n a l P r e -p r o o f 7 with the chi-squared test or the Fisher's exact test as appropriate. The association between obesity (as exposure) and COVID-19 severity (as the outcome) among MAFLD patients was assessed by binary logistic regression. Statistical analyses were two-sided and significance was set at p <0.05. All statistical tests were performed using SPSS version 23.0 (SPSS Inc., Chicago, USA).

The mean age of enrolled patients was 47 years and 74.2% were female. Table 1 shows the main clinical and biochemical characteristics of COVID-19 patients with MAFLD stratified by obesity status. Mean BMI for the non-obese and obese patients were 22.7 ±2.1 kg/m 2 and 28.3 ±3.2 kg/m 2 , respectively. Compared with the non-obese group, obese patients had higher levels of aspartate aminotransferase, fasting blood glucose and LDL-cholesterol, and lower lymphocyte counts. Notably, MALFD patients that were obese had more severe COVID-19 disease (37.5% vs.

9.5%, p =0.021). 

Our results show that in MAFLD patients with laboratory-confirmed COVID-19, the presence of obesity markedly increases the risk of having severe illness. This association remained significant after adjusting for likely confounders.

We reported previously that obesity is associated with a nearly 3-fold increased risk for severe COVID-19 with a dose-effect relationship between increasing BMI and the proportion of patients with severe illness. [11] In the current analysis, the risk of severe illness in MAFLD patients with co-existing obesity was more than 6-fold greater after adjustment for confounders. These findings are distinct, suggesting that the risk of obesity to COVID-19 severity is significantly greater in those with MAFLD. However, the virological and physiological mechanisms underlying the relationship we observed is not clarified by the present data. Systemic inflammatory J o u r n a l P r e -p r o o f 9 response syndrome, a common complication in severe COVID-19, [12] is promoted by the activation of CD14+ and CD16+ inflammatory monocytes producing a larger amount of interleukin (IL)-6 and other proinflammatory factors. This suggests IL-6 is a key proinflammatory factor that triggers the inflammatory "storm" in patients. [13] In MAFLD patients, particularly those with obesity, increased inflammatory activity in the liver and visceral fat is independently correlated with increased levels of IL-6, [14] which might have an additive/synergistic role in promoting greater severity of COVID-19. It is conceivable that the secretion of hepatokines for example, reduced adiponectin or the altered secretion of inflammatory lipid mediators in obese patients with MAFLD, [15] may also contribute to the current observations. While this is the first multi-center study to investigate obesity as a possible risk factor for severe COVID-19 illness in patients with MAFLD, some limitations should be recognized. Patients included in our study did not undergo liver biopsy, thus COVID-19 severity in relation to liver histology could not be assessed. Waist circumference, a risk factor for MAFLD, was not measured in our patients, which precluded adjustment of this confounder. In addition, patients were of Asian ethnicity and thus the applicability of the results to other ethnic groups is uncertain. Additional studies will be needed to confirm these findings and to better understand the underlying mechanisms for why the association with obesity is greater in those with 

WHO characterizes COVID-19 as a pandemic

Clinical Characteristics of Coronavirus Disease 2019 in China

A new definition for metabolic associated fatty liver disease: an international expert consensus statement

The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease is associated with decreased lung function

Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia

Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study

National Health Commission & State Administration of Traditional Chinese Medicine

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia

Obesity and Overweight in Asian People

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic medicine : a journal of the

Obesity is a risk factor for greater COVID-19 severity. Diabetes Care

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and liver dysfunc-tion: Current insights and emergent therapeutic strategies

Visceral fat: a key mediator of steatohepatitis in metabolic liver disease

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation